A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
In 1937, the Turkish physician Hulusi Behçet described a number of patients with relapsing aphthous ulcers in the mouth and over the genitalia, as well as hypopyon iritis. Since that time, the eponymous condition, known as Behçet’s disease, has been recognized as a multisystem vasculitis that can present with myriad other signs and symptoms. Although…
I couldn’t help but roll my eyes. I was at a mandatory “training session” on patient communication for all clinicians at my institution. There, I was being coached on how to properly talk to patients. In theory, this isn’t a bad thing—we all need more education on how to facilitate inclusive and equitable conversations with…
SAN DIEGO—The Accelerating Medicines Partnership (AMP) is a public-private collaboration involving the National Institutes of Health (NIH), the U.S. Food & Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations, all joined together with the goal of transforming diagnosis and treatments for a multitude of diseases. One such condition that has been…
SAN DIEGO—At ACR Convergence 2023, panelists provided guidance for reducing disparities and improving health equity for patients who are negatively impacted by social determinants of health.
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
SAN DIEGO—Panelists at ACR Convergence 2023 debate the merits of IL-6 inhibitors vs. glucocorticoids for the initial treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
SAN DIEGO—In their study, Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study, Mendel et al. assessed the relationship between trimethoprim sulfamethoxazole (TMP-SMX) and infection in patients undergoing treatment for granulomatosis with polyangiitis (GPA). Background/Purpose Infections during treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV)…
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.